GT Metabolic Solutions Announces Series C Growth Investment Led by J.P. Morgan Life Sciences Private Capital
MINNEAPOLIS — GT Metabolic™ Solutions, Inc. (“the Company” or “GT Metabolic”), a pioneer in the medical device field and the first to receive FDA De Novo grant and 510(k) clearance for use of magnetic technology to create compression anastomoses (connections between two tubular structures in the body, such as intestines), today announced a Series C […]
Read original article on Financial Post →